All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
Switzerland Vol.5 (pharmaceutical corporations: Novartis)
Switzerland Vol.6 (pharmaceutical corporations: Roche)
Switzerland Vol.7 (pharmaceutical corporations: Lonza, Actelion, Ferring Pharmaceuticals)
ツイッター検索で 上記5製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Last, reminding folks that novel pancoronavirus inhibitors are being developed by other big pharmas (Novartis, Takeda, Gilead, etc), who are moving very quickly: https://t.co/dn5JUpLXUy
— Lisa Jarvis (@lisamjarvis) September 17, 2020
Takeda just made a huge investment in cell therapy programs – a new R&D cell therapy manufacturing GMP facility in Boston. To cover 5 collab programs – Yamanaka, Rezvani, Sadelain, Noile-Immune Bio, GammaDelta Tx https://t.co/PNs2SXMubD Reminds me Novartis in the past…
— Alexey Bersenev (@cells_nnm) September 15, 2020
Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz#new
— Pharma News (@pharminews) September 8, 2020
Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia
— Pearl Freier (@PearlF) September 6, 2020
Fighting stigma — Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai …: Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer. https://t.co/AEaRUSbxKP
— STIGMABASE | EDU (@stigmabase) August 24, 2020
Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus https://t.co/bdi5MasNwb – was this the largest “de-valuation” of a #digitalhealth company ? Anyone have the stats ?
— Eugene Borukhovich (@HealthEugene) August 21, 2020
Discover the latest in the pharmaceutical legal landscape from legal experts who are shaping the landscape. Learn from, and liaise with, the likes of #Astellas Pharma, #AstraZeneca, #GSK, #Merck, #Novartis International AG, #Pfizer, #Teva, and many more! https://t.co/dqYm5O6NtJ pic.twitter.com/DJ93ECtTXO
— Pharma Regs – Informa Connect (@PharmaRegsIC) August 12, 2020
Sugar Coated Tablets Market Overview & Potential Growth Opportunities 2023| Key Players:Pfizer, Novartis, GSK & Eisai : Radiant Insights, Inc. https://t.co/0qhLWEgm0R pic.twitter.com/fAypRRPKo8
— ABNewswire (@ABNewswire) July 31, 2020
Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Novartis announces new drug approved in Japan for patients with a specific mutation in advanced non-small cell lung cancer. #NSCLC #NovartisNews
— Novartis News (@NovartisNews) June 29, 2020
Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal https://t.co/XfZZGdOed5 pic.twitter.com/lH20KeVBns
— Reuters (@Reuters) June 29, 2020
Royalty Pharma's portfolio..AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta-all pay royalties to this company https://t.co/Y3l3KZvq1c
— MedicalQuack (@MedicalQuack) June 20, 2020
Guess who are stakeholders of the NICE guidelines for psychosis?
Astrazeneca UK Ltd, Pfizer, Sanofi, Roche, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly, Janssen, Lundbeck, Novartis, Otsuka Pharmaceuticals etc.https://t.co/FQhUw8RHBz
— Nick (@NickWebb30) March 31, 2020
Well done BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the U.S. and Canada), Merck KGaA, Novartis, Pfizer, and Sanofi. https://t.co/f4ATL9azds
— Adam P Roberts (@GCAGATGCAATG) March 26, 2020
Japan approves Novartis' Zolgensma for spinal muscular atrophy in patients under two years old https://t.co/75M3RoPaHb #pharma pic.twitter.com/fBHwt0wNMU
— Pharmafocus (@Pharmafocus) March 19, 2020
https://twitter.com/Kamacintosh/status/1232044166886105089
https://twitter.com/RebeccaDRobbins/status/1222956083301322752
#Trending: Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B – Business Wire#entrepreneur #venturecapital #vc #startups
Read More Here:https://t.co/OJ7yGj7EpW
— Chuck Russell (@iamChuckRussell) January 14, 2020
Astellas Venture Management Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B: Total Series B Raise of $35 million TScan Therapeutics today announced the completion of its Series B raise with the inclusion of… https://t.co/ovyn92roLF
— Renal Cell Carcinoma (@Renal_Bio) January 9, 2020
Otsuka/Proteus, Novartis/Pear, Sanofi/Verily — pharmas & DtX partners are splitting up left and right. Should startups and investors be worried? @dave_muoio
digs in. https://t.co/vEUJmh5hrE via @MobiHealthNews— Jonah Comstock (@JonahComstock) December 16, 2019
There are examples of some big Pharma tech partnerships failing Novartis-Proteus. Otsuka-Proteus. Novartis-Pear. Sanofi now exits. But -while these experiments may not have paid off—there still seems to be appetite for innovation and AI. https://t.co/wBH4kvdTix
— Vasudev Bailey, PhD (@vasudevbailey) December 11, 2019
Biotech’s second year of red-hot takeovers is set for a strong finish with Astellas Pharma’s $3 billion buy and Novartis’s $6.8 billion deal for Medicines Co. https://t.co/H1o1vhp3vQ pic.twitter.com/TesYaDcEtn
— Bloomberg (@business) December 4, 2019
As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu
— MRVSKY (@mrvskypro) December 1, 2019
Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …
— GESDAT GmbH (@GESDAT) November 5, 2019
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Anokion helped launch the Cambridge-based start-up it acquired today, Kanyos, back in 2015. Kanyos' early backers also included Versant Ventures, Astellas, and the venture arms of Novartis and Novo Nordisk. https://t.co/R6CzYpsmWn
— Kate Sheridan (@sheridan_kate) September 11, 2019
Google sister-company Verily is teaming with big #pharma companies such as Novartis, Sanofi, Otsuka and Pfizer on clinical trials with the goal to aggregate data across a variety of sources. Read more: https://t.co/nsC84fgcWY
— BrackenData (@BrackenData) July 13, 2019
Verily has formed alliances with Novartis, Sanofi, Otsuka, and Pfizer to work on clinical trials. So, what do they get out of the deal? https://t.co/QmgSYRsMhN
— STAT (@statnews) May 26, 2019
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems. https://t.co/HiKfv83vzM
— BioSpace (@biospace) May 21, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq#R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth
— Vitaly Health (@HealthVitaly) May 19, 2019
Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800 https://t.co/dSZ1bpaPtM pic.twitter.com/pzy74432N2
— Reuters (@Reuters) May 15, 2019
Takeda selling Xiidra to Novartis: Takeda Pharmaceutical has entered into an agreement to sell Xiidra to Novartis for up to $5.3 billion. The sale will enable Takeda to focus on its key business areas of gastroenterology, rare diseases, plasma-derived… https://t.co/HnTfEdUjyK
— Keratomania | Keratoconus Advocacy Network (@Keratomania) May 9, 2019
Somewhere out there, Flemming Onskov is chuckling tonight —
Novartis buys Takeda’s new dry eye drug in $5.3B deal, hiring on 400 staffers in a blockbuster push on ophthalmology$NVShttps://t.co/Y9bP1tmV87— John Carroll (@JohnCendpts) May 8, 2019
$NVS $TAK – Novartis eyeing Takeda eye disease unit – Bloomberg https://t.co/E7Ko5Rzkxc
— Breaking News (@MarketCurrents) May 8, 2019
And another lobbyist fan of Buttieg, John Michael Gonzalez, is a DCCC bundler who reps PhRMA, Amgen, Astellas Pharma U.S., AstraZeneca, Celgene, Merck, and Novartis as well as Cigna, America’s Physician Groups and InnovaCare. https://t.co/UAnYI3VRyi https://t.co/7wAWNG5RpB
— Alex Kotch (@alexkotch) April 24, 2019
8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj— Organic Process Research & Development (@OPRD_ACS) April 5, 2019
We're excited to share that we have raised $31M from Novartis, Ping An Group, Chiesi Group, GuideWell and Otsuka to invest in Health Transformers #DigitalHealth #StartUpHealth #Moonshots https://t.co/ooWXzwiUrl
— StartUp Health (@startuphealth) September 25, 2018
Sun Pharma buys 14 drug brands from Novartis in Japan https://t.co/r8KEuqrOVT pic.twitter.com/l9MqFv1bwC
— Business Today (@BT_India) March 30, 2016
Sun Pharma agrees to buy 14 drug brands from Novartis in Japan https://t.co/hd6hsmpSKS pic.twitter.com/nq2uII5WfZ
— Hindustan Times (@htTweets) March 30, 2016
Novartis psoriasis drug approved in Japan http://t.co/THMqWEqEC3
— MarketWatch (@MarketWatch) December 26, 2014
https://twitter.com/pharmalot/status/562637508815900674
https://twitter.com/STForeignDesk/status/506366489046159360
https://twitter.com/DunyaNews/status/484281346127175680
Roche to look for approval of COVID-19, influenza test in Japan#roche #test #japan https://t.co/6xcMG2LcBO
— Breaking the News 24/7 (@Breaking24Seven) September 11, 2020
Roche Seeks Approval For Covid, Flu Combo Test In Japan – Nikkei https://t.co/2M41ejQXoG
— LiveSquawk (@LiveSquawk) September 11, 2020
The story behind the vitamin cartel of the 1990s, one of the most harmful and far-reaching cartels ever, provides a graphic example of the unscrupulous business ethics of the pharmaceutical industry.#vitamincartel #Roche #BASF #Takedahttps://t.co/qFRSiK0LYF
— Dr. Rath Foundation (@Dr_Rath_News) August 15, 2020
Chances of @Roche’s etrolizumab challenging @Takeda’s fast-growing Entyvio in the #ulcerativecolitis market look much diminished after top-line phase 3 results are revealed https://t.co/dNPqUYawVs
— pharmaphorum (@pharmaphorum) August 10, 2020
The Latest Info On Pharmaceutical Treatments And #Vaccines•#GileadSciences•#AbbVie•#Moderna•Johnson&Johnson•#EliLilly•#Pfizer•#GlaxoSmithKline•#VirBiotechnology•#Sanofi•Apeiron Biologics•#CureVac•#Dyadic•#Mesoblast•#Novavax•#Roche•#Takeda https://t.co/De0VjosMjf
— LebensKünstler (@GmmLhDBsc2heyst) March 20, 2020
https://twitter.com/IFPMA/status/1240674566214737920
The Daily Biotech Pulse: European Nod For Roche, Takeda … #biotech #bhivechat #bhivenectar #bhive https://t.co/W0wFVVxzqh
— BHIVE BioTech (@BHIVE_BioTek) September 7, 2019
Takeda v Roche: "Is it plausible? Is it true?" https://t.co/r69KeiEU09 via The IPkat pic.twitter.com/Dh88ug4qPT
— Zivko Mijatovic & Partners (@ZivkoMijatovicP) August 1, 2019
Xconomy – #Bio #Roundup: #Alzheimer’s Fail, #Drug #Price #Plan, #Gene #Therapies & #DRUG #DEVELOPMENTS https://t.co/QWpLu146cB #JnJ #Roche #Sunovion #Alexion #Takeda #Pfizer #Lilly …
— GESDAT GmbH (@GESDAT) February 1, 2019
At $74B, $BMS's $CELG deal is the largest ever outlay for a biotech takeout, topping Takeda-Shire. In terms of valuation, the deal is second only to Genentech’s '09 acquisition by Roche. Read more on today's pre #JPM2019 mega-deal in @BioCentury Extra: https://t.co/nC6wKWZxUW pic.twitter.com/EULYhKBfic
— BioCentury (@BioCentury) January 3, 2019
Japan approves Roche's entrectinib in tissue-agnostic indication, Daiichi's AML therapy quizartinib, Alnylam's Onpattro and Alexion's Ultomiris $ROG $ALNY $ALXN https://t.co/TON7QXZX5d
— BioCentury (@BioCentury) June 18, 2019
BioCentury's Sept. 12 clinical roundup includes Celgene plans for regulatory submission in AML on Phase III meet; plus clinical updates from Roche, Tocagen, Adverum, Daiichi Sankyo and more $ROG $TOCA $ADVM $APPL https://t.co/MEXuxEYsAm
— BioCentury (@BioCentury) September 13, 2019
BioCentury's March 26 product development roundup includes approval of Pear's digital therapeutic for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax $JAZZ https://t.co/W7EATOXux0
— BioCentury (@BioCentury) March 27, 2020
https://twitter.com/RebeccaDRobbins/status/1222956083301322752
Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql
— Science Examiner (@ScienceExaminer) October 7, 2019
AstraZeneca and Daiichi Sankyo to jointly develop cancer drug https://t.co/bISxvzKf94 pic.twitter.com/BYUzQaMd4B
— Reuters Business (@ReutersBiz) March 29, 2019
AstraZeneca Plc will pay up to $6.9 billion (5.2 billion pounds) to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.
"AstraZeneca pays up to… https://t.co/4TTdJW5BNp
— kristoferkawas (@kristoferkawas) March 29, 2019
Interested in #immunotherapy & #immunohistochemistry?
Check out DDNews’ e-news w/ stories from MorphoSys, Roche, Daiichi Sankyo & UCSD
PLUS resources from sponsor Cell Signaling Technologyhttps://t.co/ueiomZAZMq#immunooncology #diagnostics #antibodies #CellTherapy #microRNA pic.twitter.com/IwTXzDT7s3
— DDNews Online (@DDNewsOnline) February 15, 2019
UK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Roche’s pipeline that could be used in a rare tendon sheath cancer already targeted by Daiichi Sankyo https://t.co/Olet72u08f
— pharmaphorum (@pharmaphorum) August 12, 2020
Lung Cancer Therapeutics Market Research, Recent Trends and Growth Forecast 2027 | #Roche, #Eli Lilly and company, #Pfizer, #Agennix AG and #Snaofi-Aventis, #Daiichi Sankyo, #AstraZeneca, #GlaxoSmithKlinehttps://t.co/kQhkhOLn48
— A2ZMarketResearch (@A2ZResearch) July 31, 2020
Major Players in the #Musculoskeletal #Disorders #Drugs #Market are F. Hoffmann-La Roche Ltd; GlaxosmithKline Plc; Pfizer Inc; Abbott Laboratories Inc; Daiichi Sankyo Company
Read More @ https://t.co/zAg48gjJ1d#marketresearch #research #TBRC pic.twitter.com/CgSHsx04l1
— Sreeramakrishna TBRC (@sreeramtbrc) June 5, 2020
ASCO: In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn't https://t.co/QH4teeefRW
— EIPG (@EIPGeu) May 30, 2020
https://twitter.com/HAccordingly/status/1221321860236955649
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campushttps://t.co/OcqukRYGP5
— John Carroll (@JohnCendpts) August 11, 2020
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc
— FiercePharma (@FiercePharma) July 8, 2020
https://twitter.com/ResearchNews_24/status/1154008113730576384
Lonza Reaches Milestone with Takeda – https://t.co/uYf0bWpOmB pic.twitter.com/oqJ37NniGt
— GMPnews.Net (@GMPnewsNet) January 14, 2019
Lonza, Takeda reach regulatory milestone in oncology tie-up https://t.co/chKQ0JKFRx
— Cleanroom Supplies (@Cleanroomsupply) January 18, 2019
https://twitter.com/JanssenAP/status/1177073498864279552
Sphingosine 1-Phosphate Receptor 1 Market to See Major Growth by 2025 | Actelion, Arena Pharmaceuticals, Astellas Pharma,… https://t.co/JV6hlVG9tZ >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #CI pic.twitter.com/odm4opMknO
— Dr Timos Papagatsias (@_timos_) February 19, 2019
Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL#news #pharma #pharmiweb
— Pharma News (@pharminews) June 23, 2020
Global Prostate Cancer Therapeutics Market In-Depth Research on industry & Emerging Growth Factors || Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inchttps://t.co/fFjHRbxhKX#new
— Pharma News (@pharminews) March 23, 2020
Increase in research & development in oncology therapeutic area is Driving The Global Prostate Cancer Therapeutics Market with Higher CAGR | Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical… https://t.co/fSa9mrn6wy pic.twitter.com/asxRZ4JUMe
— Oncology Board (@mb_Oncology) September 21, 2019
